Form 4: C4 Therapeutics Executive Boyle Receives Option Repricing

Scott N. Boyle, Chief Business Officer of C4 Therapeutics, Inc., had stock options repriced on March 7, 2024, according to a recent SEC filing.

Summary

• Scott N. Boyle, Chief Business Officer of C4 Therapeutics, Inc. [CCCC], had changes in beneficial ownership reported on March 8, 2024.
• The earliest transaction date was March 7, 2024.
• The filing indicates an option repricing approved by the Compensation Committee of the Issuer's Board of Directors on March 7, 2024.
• An existing stock option for 115,000 shares with an exercise price of $33.23 was repriced.
• A new stock option for 115,000 shares was acquired with an exercise price of $19.
• 25% of the shares underlying the option vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
• All other terms of the options remain unchanged.

Sentiment

Score: 6

Explanation: The sentiment is neutral. Option repricing can be seen as a positive sign of the company's commitment to its executives, but it also suggests that the stock price may not have performed as expected.

Positives

• The option repricing could incentivize the executive to improve company performance.

Industry Context

Option repricing is a tool companies use to re-incentivize employees when the stock price has fallen significantly below the original option exercise price. It's common in the biotech industry, which can be volatile.

Comparison to Industry Standards

• Option repricing is a fairly common practice, especially in volatile sectors like biotechnology.
• Many companies, including those in the Russell 2000, have used this mechanism to retain and motivate key employees when stock prices decline.
• The specific terms, such as the new exercise price and vesting schedule, would need to be compared to similar companies to assess if they are in line with industry standards.

Stakeholder Impact

• Shareholders may view the option repricing as a necessary measure to retain key talent.
• Employees, particularly the executive receiving the repriced options, are likely to be positively impacted due to the increased potential for financial gain.
• The repricing has no immediate impact on customers, suppliers, or creditors.

Key Dates